Cancer survivors may experience more challenges to adopt a child
the ONA take:
According to a recent study published online ahead of print in the journal Cancer, researchers have found that cancer survivors' options for adoption may be limited by adoption agencies' policies.
Many young cancer survivors often opt to adopt to a child after cancer and cancer therapies leave some patients infertile; however, not only is adoption a long and costly process, but some adoption agencies also have policies that may prevent cancer survivors from being able to adopt.
For the study, oncology nurses participating in a training program contacted and interviewed adoption agencies about the costs and requirements for adoption. the nurses found that adoption fees ranged from $3,000 to $75,000. They also found that a few agencies believed it could be discouraging for a birth mother to have an adoptive parent with a history of cancer, while others reported that a history of cancer could make birth mothers feel optimistic and confident.
The study also helped oncology nurses to become more knowledgeable about the challenges of adoption in cancer survivors, and study authors hope that this experience will help them to better inform their patients on parenthood options in the future.
Researchers have found that cancer survivors' options for adoption may be limited by adoption agencies' policies.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
- FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|